Glaukos Corp (STU:6GJ)
€ 119 0 (0%) Market Cap: 6.82 Bil Enterprise Value: 6.73 Bil PE Ratio: 0 PB Ratio: 11.05 GF Score: 64/100

Glaukos Corp at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 07:00PM GMT
Release Date Price: €63 (+0.80%)
Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst

Good afternoon, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Very happy to introduce our next company. It's going to be CEO, Tom Burns, presenting for Glaukos. Lots of news flow today from the company. I feel honored. It's like a mini analyst day they've provided the JPMorgan conference here.

So before we get to that, everyone can go to the conference website and follow along with the slide deck. You could submit a question there or you could e-mail me or chat me on Bloomberg, and I'll do my best to get to all the questions in Q&A. So with that, Tom, I'll turn it over to you.

Thomas William Burns
Glaukos Corporation - CEO, President & Director

Thank you very much, Robbie, and appreciate you having the access for the company today. I'm delighted to give an update on Glaukos Corporation and really want to talk about from the inception of this company, our mission has been to transform glaucoma therapy. And in doing so, we founded an entirely new

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot